Home › COPD › Texas

Pag-aaral pangklinika para sa COPD sa Texas

25 pag-aaral para sa COPD ang naghahanap ng mga kalahok sa mga site sa Texas.

Mga Lungsod sa Texas

Opisyal na teksto ng pag-aaral (English)

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Copd01 50001, Boerne

Nagre-recruitPhase 2

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07725939

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Premier Pulmonary Critical Care and Sleep, Denison
Baylor College of Medicine Medical Center, Houston
Prime Clinical Research - Lewisville, Lewisville

Nagre-recruitPhase 2

Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07759245

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

REX Clinical Trials - Beaumont- Site Number : 8400011, Beaumont

Nagre-recruitPhase 4

Edad 40 hanggang 85 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07053423

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Wellness Clinical Research - Allen- Site Number : 8400085, Allen
REX Clinical Trials - Beaumont- Site Number : 8400014, Beaumont
Novel Research - Bellaire- Site Number : 8400116, Bellaire
at 17 pa

Nagre-recruitPhase 3

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07190209

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

University of Texas Southwestern, Dallas

Nagre-recruit

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06035120

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

WB Contracted Clinical Research Site, McKinney
WB Contracted Clinical Research Site, Waxahachie

Nagre-recruitPhase 2

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07646587

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

IntraCare- Site Number : 8400034, Dallas
Premier Pulmonary Critical Care and Sleep- Site Number : 8400111, Denison
El Paso Pulmonary Association- Site Number : 8400033, El Paso
at 5 pa

Nagre-recruitPhase 3

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07190222

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Research Site, Boerne
Research Site, Dallas
Research Site, Denison
at 5 pa

Nagre-recruitPhase 2

Edad 40 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07082738

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

Baylor College of Medicine, Houston

Nagre-recruitPhase 2

Edad 40 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07059091

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Research Site, Boerne
Research Site, El Paso
Research Site, Houston
at 6 pa

Nagre-recruitPhase 3

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Research Site, Dallas
Research Site, Forney
Research Site, Fort Worth
at 5 pa

Nagre-recruitPhase 3

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06883305

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

The Lung & Sleep Institute of North Texas, North Richland Hills

Nagre-recruitObservasyonal na pag-aaral

Edad 40 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07612878

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

South Texas Medical Research Institute, Inc., DBA TTS Research, Boerne
Ten20 Clinical Research, Carrollton
Horizon Clinical Research Group, Cypress
at 4 pa

Nagre-recruitPhase 2/3

Edad 35 hanggang 80 · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07363694

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Research Site, Abilene
Research Site, Brownsville
Research Site, Dallas
at 12 pa

Nagre-recruitPhase 3

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06283966

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

GC2501 Study Site 109, Dallas

Nagre-recruitPhase 3

Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT07555483

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

Horizon Clinical Research Group., Cypress
DM Clinical Research- Tomball, Tomball

Nagre-recruitPhase 2

Edad 40 hanggang 85 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT07684820

STRIVE Post-Market Registry Study

Baylor Scott & White Research Institute, Dallas
University of Texas Southwestern, Dallas
University of Texas Health Science Center at Houston, Houston

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT04302272

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

GSK Investigational Site, Dallas
GSK Investigational Site, DeSoto
GSK Investigational Site, Greenville
at 6 pa

Nagre-recruitPhase 3

Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07177339

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Liver Center of Texas, Dallas
Methodist Hospital, Richardson

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 10, 2026 · NCT05181826

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

Houston Methodist/Primary Critical Care, Houston

Nagre-recruit

Edad 40 hanggang 84 · Lahat ng kasarian · Na-update Abr 24, 2026 · NCT06891755

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

GSK Investigational Site, Austin
GSK Investigational Site, Dallas
GSK Investigational Site, El Paso
at 5 pa

Nagre-recruitPhase 3

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06961214

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

GSK Investigational Site, Corsicana

Nagre-recruitPhase 3

Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Okt 8, 2025 · NCT06959095

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

Texas A&M Family Care, Bryan

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Set 12, 2025 · NCT06726590

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Horizon Clinical Research Group, Houston
CHRISTUS Trinity Mother Frances Health System, Tyler

Nagre-recruitObservasyonal na pag-aaral

Edad 50 pataas · Lahat ng kasarian · Na-update Ago 5, 2025 · NCT06122077

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Respire Research Institute, Houston

Nagre-recruit

Edad 30 pataas · Lahat ng kasarian · Na-update Peb 6, 2025 · NCT05204888

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.